For the second time in two months, Celcuity Inc. failed to generate investor excitement despite disclosing positive news, this time following the U.S. FDA approval of Revtorpyk (gedatolisib) in a subset of breast cancer patients, marking the firm’s first foray into the commercial space and introducing a new treatment option for patients. Wall Street instead focused on an unanticipated launch delay, sending shares of Celcuity (NASDAQ:CELC) down 17.6% to close July 15 at $91.51.

Coregen Inc. has obtained IND clearance from the FDA for CRG-150, a novel adoptive cell therapy targeting SRC-3 (steroid receptor coactivator 3).

Astex Pharmaceuticals Ltd. has entered into an exclusive, worldwide research collaboration and license agreement with Genentech Inc., a member of the Roche Group, to identify small-molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer.

Researchers at Theramir Ltd. presented preclinical proof-of-concept data for a new extracellular vesicle (EV) platform engineered to deliver miR-885-5p (EVmiR885-5p), targeting leukocyte-specific protein-1 (LCP-1)-mediated cytoskeletal remodeling in triple-negative breast cancer (TNBC) models.

Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam.

Mammogen Inc. raised $30 million in equity financing in a series A round to support the clinical advancement and commercialization of its RNA-powered molecular diagnostics platform. The company’s lead product is Gentru-breast, a blood-based assay designed to detect molecular signatures associated with breast cancer from a simple blood draw.

Minneapolis-based Celcuity Inc. was like the Rolling Stones at the 2026 American Society of Clinical Oncology annual meeting. The company reported positive phase III data for its pan-PI3K/mTORC1/2 inhibitor gedatolisib, but Celcuity (NASDAQ:CELC) couldn’t get any satisfaction from investors who sent shares down 25.7%, or $31.54, to $91.42 on June 2, 2026.

Iovance Biotherapeutics Inc. has received IND clearance from the FDA for IOV-5001, a next-generation interleukin-12 (IL-12)-tethered tumor-infiltrating lymphocyte (TIL) therapy.

Alaw Therapeutics Inc. has announced the nomination of AL-433, a selective, brain-penetrant CDK4 inhibitor, as a development candidate.

Kolon Life Science Inc. is developing KLS-3021, a next-generation oncolytic vaccinia virus designed to express the PH20, IL-12 and PD-1-Fc transgenes to mediate receptor-independent tumor cell killing and enhance antitumor immune responses.